Orchestra BioMed Holdings (OBIO) Revenue (2022 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Revenue of $110000.0 for Q1 2026, down 87.33% year-over-year from $868000.0 in Q1 2025, and down 99.64% quarter-over-quarter from $30.9 million in Q4 2025.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) Revenue (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Revenue for 5 consecutive years, with $110000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue fell 87.33% year-over-year to $110000.0; the TTM figure through Mar 2026 stood at $32.7 million (up 1033.89% YoY), while the FY2025 annual figure was $33.5 million, up 1169.22% from the prior year.
- Revenue declined to $110000.0 in Q1 2026 per OBIO's latest filing, from $30.9 million in the prior quarter.
- Across five years, Revenue topped out at $30.9 million in Q4 2025 and bottomed at $110000.0 in Q1 2026.
- Historically, Revenue has averaged $2.5 million across 5 years, with a median of $861000.0 in 2025.
- Annual changes were most pronounced in 2025 — Revenue jumped 12120.16% — and 2026, when it sank 87.33%.
- Orchestra BioMed Holdings' Revenue stood at $1.1 million in 2022, then sank by 76.25% to $262000.0 in 2023, then slipped by 3.44% to $253000.0 in 2024, then surged by 12120.16% to $30.9 million in 2025, then tumbled by 99.64% to $110000.0 in 2026.
- Business Quant data shows OBIO's Revenue at $110000.0 in Q1 2026, $30.9 million in Q4 2025, and $861000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | 145.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 1.71 Bn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 674.14 Mn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Orchestra BioMed Holdings | 314.27 Mn | 119.74 Mn | 63,000.00 | 88,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 88,000.00 |
| Mar 31, 2026 | 110,000.00 |
| Dec 31, 2025 | 30.92 Mn |
| Sep 30, 2025 | 861,000.00 |
| Jun 30, 2025 | 836,000.00 |
| Mar 31, 2025 | 868,000.00 |
| Dec 31, 2024 | 253,000.00 |
| Sep 30, 2024 | 987,000.00 |
| Jun 30, 2024 | 778,000.00 |
| Mar 31, 2024 | 620,000.00 |
| Dec 31, 2023 | 262,000.00 |
| Sep 30, 2023 | 419,000.00 |
| Jun 30, 2023 | 915,000.00 |
| Mar 31, 2023 | 1.16 Mn |
| Dec 31, 2022 | 1.10 Mn |
| Sep 30, 2022 | 1.16 Mn |
| Jun 30, 2022 | 401,000.00 |
| Mar 31, 2022 | 866,000.00 |